| Literature DB >> 15987196 |
Paul A Wender1, Martin Sukopp, Kate Longcore.
Abstract
[reaction: see text] Apoptolidin (1) is a promising new therapeutic lead that exhibits remarkable selectivity against cancer cells relative to normal cells. We report the isolation, characterization, solution structure, stability, and biological activity of two new members of this family: apoptolidins B (2) and C (3). These new agents are found to have antiproliferative activity on par with or better than apoptolidin itself in an assay with H292 lung cancer cells.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15987196 PMCID: PMC2533581 DOI: 10.1021/ol051074o
Source DB: PubMed Journal: Org Lett ISSN: 1523-7052 Impact factor: 6.005